Pacira BioSciences, Inc.
Pacira BioSciences develops, manufactures, markets, and sells non-opioid pain management solutions. Products include EXPAREL, ZILRETTA, and iovera system. The company has a development agreement with Aratana Therapeutics for NOCITA. Pacira was previously known as Pacira Pharmaceuticals before changing its name in 2019.
Overview
Strengths
- Price to book ratio (1.32) is lower than the sector mean (733.70).
- EV/EBITDA (6.96) is lower than the sector mean (51.86).
- Price to free cash flow (5.77) is lower than the sector mean.
- Strong EBITDA Margin of 27.47%.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 6.8 |
| Price/Free Cash Flow' | 5.6 |
| ROIC | 13.9% |
| Net Debt/EBITDA | 1.6 |